MX2021012870A - Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias. - Google Patents

Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.

Info

Publication number
MX2021012870A
MX2021012870A MX2021012870A MX2021012870A MX2021012870A MX 2021012870 A MX2021012870 A MX 2021012870A MX 2021012870 A MX2021012870 A MX 2021012870A MX 2021012870 A MX2021012870 A MX 2021012870A MX 2021012870 A MX2021012870 A MX 2021012870A
Authority
MX
Mexico
Prior art keywords
antibody
autoimmune disease
treat autoimmune
treat
vib551
Prior art date
Application number
MX2021012870A
Other languages
English (en)
Inventor
Jorn Drappa
Eliezer Katz
Kathleen Mckeever
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of MX2021012870A publication Critical patent/MX2021012870A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se desvelan métodos de uso de un anticuerpo anti CD19 para tratar enfermedades autoinmunitarias. En particular, el uso de VIB551, un anticuerpo monoclonal de IgG1 kappa afucosilado, humanizado, optimizado por afinidad, para tratar el trastorno del espectro de la neuromielitis óptica.
MX2021012870A 2019-04-24 2020-04-23 Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias. MX2021012870A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962838093P 2019-04-24 2019-04-24
US201962843096P 2019-05-03 2019-05-03
US201962858495P 2019-06-07 2019-06-07
PCT/US2020/029613 WO2020219743A2 (en) 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (1)

Publication Number Publication Date
MX2021012870A true MX2021012870A (es) 2022-01-18

Family

ID=72940915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012870A MX2021012870A (es) 2019-04-24 2020-04-23 Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.

Country Status (12)

Country Link
US (1) US20220204617A1 (es)
EP (1) EP3959241A4 (es)
JP (1) JP2022529743A (es)
KR (1) KR20220004113A (es)
CN (1) CN113939532A (es)
AU (1) AU2020263418A1 (es)
BR (1) BR112021020924A2 (es)
CA (1) CA3136487A1 (es)
IL (1) IL287385A (es)
MX (1) MX2021012870A (es)
SG (1) SG11202111429UA (es)
WO (1) WO2020219743A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809260A1 (de) * 2019-10-18 2021-04-21 Siemens Healthcare GmbH System und verfahren zur administration von bildgebenden geräten
KR20240004367A (ko) * 2021-05-07 2024-01-11 비엘라 바이오, 인크. 중증근무력증 치료를 위한 항-cd19 항체의 사용
WO2024025602A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. Inebilizumab and methods of using the same for sustained b-cell depletion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101456728B1 (ko) * 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
BRPI1013237A2 (pt) * 2009-03-06 2019-09-24 Medimmune Llc formulação aquosa estável, estéril, forma de dosagem unitária farmacêutica, recipiente vedado, kit, métodos para tratar um distúrbio ou doença de células b em um humano, para esgotar células b que expressam cd-19 em um paciente humano, e para intensificar a estabilidade de armazenamento de uma formulação aquosa, e, processo para preparar uma formulação
EP2827902A4 (en) * 2012-03-12 2016-01-20 Medimmune Llc TREATMENT OF MULTIPLE SCLEROSIS WITH ANTI-CD19 ANTIBODY
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease

Also Published As

Publication number Publication date
EP3959241A2 (en) 2022-03-02
CN113939532A (zh) 2022-01-14
US20220204617A1 (en) 2022-06-30
BR112021020924A2 (pt) 2022-04-19
EP3959241A4 (en) 2023-01-25
IL287385A (en) 2021-12-01
WO2020219743A3 (en) 2020-12-10
JP2022529743A (ja) 2022-06-23
KR20220004113A (ko) 2022-01-11
AU2020263418A1 (en) 2021-11-11
CA3136487A1 (en) 2020-10-29
SG11202111429UA (en) 2021-11-29
WO2020219743A2 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
MX2021012870A (es) Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
EA200970556A1 (ru) Моноклональные антитела против angptl3
PH12020551970A1 (en) Anti-muc1 antibody
WO2017004026A8 (en) Anti-cd123 antibodies and conjugates and derivatives thereof
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
ZA202008095B (en) Humanized antibodies against psma
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2023004275A (es) Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
EP4029878A4 (en) HUMAN MONOCLONAL ANTIBODY TARGETING YKL-40
MX2021000797A (es) Anticuerpos agonistas de cd226.
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
IL276211A (en) Process for producing hu14.18k322a monoclonal antibody
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
EP3762027A4 (en) THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
CO2022009246A2 (es) Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis óptica
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
MX2023005699A (es) Anticuerpos biespecificos para el uso en el tratamiento de inflamasomopatia nlrc4-gof.